Open AccessTacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement
Author(s) -
Iain MacPhee,
Salim Fredericks,
Tracy W Tai,
Petros Syrris,
Nicholas D. Carter,
Atholl Johnston,
Lawrence Goldberg,
David W. Holt
Publication year - 2002
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-200212150-00002
Subject(s) - tacrolimus , genotype , cyp3a5 , pharmacogenetics , genotyping , biology , pharmacology , p glycoprotein , single nucleotide polymorphism , transplantation , medicine , gastroenterology , drug resistance , genetics , gene , multiple drug resistance
There is marked heterogeneity in blood concentrations of tacrolimus following standard body-weight-based dosing. This is most apparent in black patients, who have a higher dose requirement when compared with other ethnic groups. Differences in intestinal P-glycoprotein and hepatic and intestinal cytochrome P4503A activity have been postulated as contributing to this problem.